Rapid Targeted Next-Generation Sequencing Platform for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

[1]  K. Ye,et al.  Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population: the Dai nationality, China , 2017, Genetics in Medicine.

[2]  R. Wapner,et al.  Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening , 2016 .

[3]  A. Perkins,et al.  Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. , 2016, Blood.

[4]  Clara Gaff,et al.  Patient safety in genomic medicine: an exploratory study , 2016, Genetics in Medicine.

[5]  P. Moi,et al.  A genetic score for the prediction of beta-thalassemia severity , 2015, Haematologica.

[6]  M. Weiss,et al.  Anemia: progress in molecular mechanisms and therapies , 2015, Nature Medicine.

[7]  J. Traeger-Synodinos,et al.  EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies , 2014, European Journal of Human Genetics.

[8]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[9]  Åsa K. Björklund,et al.  Tn5 transposase and tagmentation procedures for massively scaled sequencing projects , 2014, Genome research.

[10]  D. Weatherall,et al.  The α-thalassemias. , 2014, The New England journal of medicine.

[11]  Tizhen Yan,et al.  KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. , 2014, Blood.

[12]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[13]  Niru Chennagiri,et al.  Validation for clinical use of, and initial clinical experience with, a novel approach to population-based carrier screening using high-throughput, next-generation DNA sequencing. , 2014, The Journal of molecular diagnostics : JMD.

[14]  Marcia M. Nizzari,et al.  Next-generation carrier screening , 2013, Genetics in Medicine.

[15]  S. Thein.  Genetic association studies in β-hemoglobinopathies. , 2013, Hematology. American Society of Hematology. Education Program.

[16]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[17]  V. Marx.  Biology: The big challenges of big data , 2013, Nature.

[18]  E. Vichinsky.  Clinical manifestations of α-thalassemia. , 2013, Cold Spring Harbor Perspectives in Medicine.

[19]  Heidi L Rehm,et al.  New approaches to molecular diagnosis. , 2013, JAMA.

[20]  Jessica X Chong,et al.  A population-based study of autosomal-recessive disease-causing mutations in a founder population. , 2012, American journal of human genetics.

[21]  D. Weatherall,et al.  World distribution, population genetics, and health burden of the hemoglobinopathies. , 2012, Cold Spring Harbor perspectives in medicine.

[22]  Philippe Joly,et al.  Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach , 2011, Nature Genetics.

[23]  E. Vichinsky,et al.  Heterogeneity of hemoglobin H disease in childhood. , 2011, The New England journal of medicine.

[24]  Andrew C. Adey,et al.  Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition , 2010, Genome Biology.

[25]  Maxine Sun,et al.  Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China , 2010, Clinical genetics.

[26]  D. Weatherall,et al.  The importance of micromapping the gene frequencies for the common inherited disorders of haemoglobin , 2010, British journal of haematology.

[27]  B. Pégourié,et al.  Complications and treatment of patients with β-thalassemia in France: results of the National Registry , 2010, Haematologica.

[28]  Serena Sanna,et al.  Amelioration of Sardinian beta0 thalassemia by genetic modifiers. , 2009, Blood.

[29]  D. Weatherall,et al.  Disorders of Hemoglobin: THE MOLECULAR, CELLULAR, AND GENETIC BASIS OF HEMOGLOBIN DISORDERS , 2009 .

[30]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[31]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[32]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[33]  W. Miller,et al.  HbVar database for human hemoglobin variants and thalassemia mutations , 2007 .

[34]  M. Petrou,et al.  Screening extended families for genetic hemoglobin disorders in Pakistan. , 2002, The New England journal of medicine.

[35]  T. Somervaille.  Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management , 2001 .

[36]  P. Vyas,et al.  The α‐Thalassemias , 1990, Annals of the New York Academy of Sciences.

[37]  D. Loukopoulos,et al.  Prevention of thalassemia. , 1983, Schweizerische medizinische Wochenschrift.

[38]  S. Orkin.  The alpha thalassemias. , 1980, Texas reports on biology and medicine.